BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | May 23, 2018
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BioCentury | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

In a Nature Communications study , scientists at University Health Network and University of Toronto showed that inhibiting histone methyltransferase DOT1L or promoting dual specificity phosphatase 6 (DUSP6; MKP3) could help prevent graft-versus-host disease induced by...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

...TRPV1; VR1) that could help treat inflammatory pain. Peking University Distillery Therapeutics Biomarkers Cancer NSCLC Dual specificity phosphatase 7...
BioCentury | Feb 8, 2018
Translation in Brief

Diverging pathways

...European American tumors, and linked that finding to the fact that the miR-191 target gene dual specificity phosphatase 7...
...from African Americans and European Americans.” Clinical Cancer Research (2017) Jennie Walters, Staff Writer National Institutes of Health Dual specificity phosphatase 7...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

INDICATION: Depression Patient sample and mouse studies suggest promoting DUSP3 expression could help treat major depressive disorder (MDD) in female patients. In postmortem tissue samples from the ventromedial prefrontal cortex of 26 MDD patients and...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BioCentury | Apr 25, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest antagonizing CD124 or promoting DUSP4 expression could help treat breast cancer. In patients, low levels of the DUSP4 negative regulator IL-4 , and high levels...
BioCentury | Mar 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML) In vitro and mouse studies suggest combining Gleevec imatinib with inhibition of c-fos and DUSP1 could help treat CML. In patient peripheral blood monocytes (PBMCs), levels of c-fos and DUSP1...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest fecal microbiotal transplants from DUSP6 -deficient donors could help treat obesity. In mice fed a high-fat diet, DUSP6 knockout decreased the permeability of gut epithelial cells and weight gain compared...
Items per page:
1 - 10 of 21